The Europe Cellular Health Screening Market would witness market growth of 8.7% CAGR during the forecast period (2022-2028).
Compound library screening for effects on living cells has evolved over the past ten years into a crucial and essential phase in almost every drug discovery effort. This strategy emerged from the awareness that biochemical assay-based screening campaigns, while incredibly productive, had fallen short of their promise to produce safer and more effective medications. The obvious benefit of screening utilizing cell-based assays is the ability to assess a compound's effects against molecular targets while it is still in a living cell.
However, screening also permits broad, systems biology techniques to study cellular pathways implicated in disease processes. In fact, cell-based diagnostic technologies have made it possible for researchers studying drug discovery to create models of interlinked cellular pathways, gather crucial data for particular disease models, and create companion diagnostics based on pertinent cellular biomarkers for treatments.
Cell-based screening automated systems are developing. The potential to screen substances against druggable targets in the regard of living cells has essentially become standard practice in both secondary and primary drug-screening programs, ranging from straightforward cell-based fluorescent, luminescent, colorimetric, and radiologic plate reader assays to real-time intracellular calcium feedback measurement techniques and high-content fluorescent imaging systems.
The EU recently introduced a novel strategy to assist Member States in boosting cancer screening uptake as a component of the EU Cancer Screening Scheme to be proposed under Europe's Beating Cancer Plan. The goal of the new guideline is to increase screenings, covering additional target groups and malignancies, with a focus on early cancer diagnosis. According to the European Commission, by 2025, 90% of EU citizens who are eligible for breast, cervical, and colorectal cancer examinations will be provided with such screenings owing to a new EU strategy that is based on the most recent scientific advancements and data. The revised guideline also includes lung, prostate, and, in some cases, stomach cancers in population-based organized cancer screening.
The Germany market dominated the Europe Cellular Health Screening Market by Country in 2021; thereby, achieving a market value of $278.2 million by 2028. The UK market would witness a CAGR of 7.8% during (2022 - 2028). Additionally, The France market is anticipated to grow a CAGR of 9.6% during (2022 - 2028).
Based on Sample Type, the market is segmented into Blood, Saliva, Serum, and Urine. Based on Collection Site, the market is segmented into Hospital, Diagnostic Labs, Home, and Office. Based on Test Type, the market is segmented into Single Test Panels and Multi-test Panels. Based on Single Test Panels Type, the market is segmented into Oxidative Stress Tests, Inflammation Tests, Telomere Tests, and Heavy Metals Tests. The report also covers geographical segmentation of Cellular Health Screening market. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Cellular Health Screening Market will Hit $4.3 Billion by 2028, at a CAGR of 9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Quest Diagnostics Incorporated, OPKO Health, Inc., Laboratory Corporation of America Holdings, Genova Diagnostics, Telomere Diagnostics, Inc., Life Length, S.L., Repeat Diagnostics, Inc., SpectraCell Laboratories, Inc. (Beingmate Group Co. Ltd.), Cell Science Systems Corp. and Segterra, Inc.
By Sample Type
By Collection Site
By Test Type
By Country
Companies Profiled
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
